Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR molecules.
Scribe Therapeutics has raised $7.5M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2026.
Scribe Therapeutics's investors include Andreessen Horowitz, Wellington Management, Menlo Ventures, RA Capital Management, Sanofi.
Scribe Therapeutics is headquartered in Alameda, United States.
Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR molecules.
Scribe Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Scribe Therapeutics — Funding & Investors." VCBacked, July 24, 2026, https://www.vcbacked.co/company/scribe-therapeutics. Accessed August 14, 2026.
VCBacked. (2026). Scribe Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/scribe-therapeutics
{{cite web |title=Scribe Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/scribe-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated